Published on 7 Oct 2024 on GuruFocus.com · via Yahoo Finance
Harmony Biosciences Holdings Inc (HRMY) Q2 2024 Earnings Call Highlights: Strong...
Net Revenue: $172.8 million, representing 29% growth year-over-year.Net Income (Non-GAAP): $60.6 million, or $1.5 per diluted share.Cash, Cash Equivalents, and Investments: $434.1 million as of June 30, 2024.2024 Revenue Guidance: $700 million to $720 million.Average Number of Patients on WAKIX: Approximately 6,550 in Q2.WAKIX Net Sales: $172.8 million for the quarter.R&D Expenses: $25.5 million charge for Bioprojet sublicensing and $17.1 million IP and R&D charge for Epygenix acquisition.
Warning! GuruFocus has detected 3 Warning Sign with AHCO.